Penghua CSI Chinese Medicine ETF(159647) Falls 0.43%, with Intraday Turnover Rate of 0.81% and Trading Volume of 11.6688 Million Yuan

NewTimeSpace News: As of 13:39 on April 20, 2026, the CSI Traditional Chinese Medicine Index (930641) fell 0.38%. Constituent stocks showed mixed performance: Mayinglong led the gains with a 1.41% rise, Longshen Rongfa rose 1.17%, and China Resources Jiangzhong rose 0.85%; Conba led the decline with a 1.71% drop, Jilin Aodong fell 1.37%, and Zhongsheng Pharmaceutical fell 1.36%.

Penghua CSI Chinese Medicine ETF(159647) declined 0.43% to a latest price of 0.93 yuan.

(The stocks listed above are index constituents only and do not constitute specific investment recommendations.)

In terms of liquidity, Penghua CSI Chinese Medicine ETFrecorded an intraday turnover rate of 0.81% with a trading volume of 11.6688 million yuan. As of April 17, its average daily trading volume over the past year reached 31.1616 million yuan.

In terms of scale, Penghua CSI Chinese Medicine ETFsaw its asset size increase by 16.6924 million yuan in the past week, marking notable growth, with the incremental scale ranking in the top 1/4 among comparable funds.

(Data source: Wind)

In terms of shares, Penghua CSI Chinese Medicine ETFadded 10.5 million units in the past week, achieving obvious growth, with the incremental shares also ranking in the top 1/4 among comparable funds.

(Data source: Wind)

In terms of capital flows, Penghua CSI Chinese Medicine ETFposted a latest net capital inflow of 3.7291 million yuan. Over the past 5 trading days, capital inflows occurred on 4 days, attracting a total of 43.6115 million yuan, representing an average daily net inflow of 8.7223 million yuan.

(Data source: Wind)

In terms of profitability, as of April 17, 2026, since its inception, Penghua CSI Chinese Medicine ETFachieved a maximum single-month return of 16.26%, the longest consecutive rising months of 5 months with a cumulative increase of 20.28%, and an average return of 4.98% in rising months. As of April 17, 2026, the fund outperformed its benchmark by an annualized return of 2.72% over the past two years, ranking in the top 1/4 among comparable funds.

In terms of drawdown, as of April 17, 2026, the fund’s maximum drawdown since the beginning of the year was 8.99%, with a relative drawdown against its benchmark of 0.06%, the smallest drawdown among comparable funds.

In terms of fees, Penghua CSI Chinese Medicine ETFcharges a management fee of 0.50% and a custody fee of 0.10%, the lowest fee level among comparable funds.

In terms of tracking accuracy, as of April 17, 2026, the fund’s tracking error over the past six months was 0.024%, representing the highest tracking accuracy among comparable funds.

From a valuation perspective, the CSI Traditional Chinese Medicine Index tracked by Penghua CSI Chinese Medicine ETFhas a latest price-to-earnings ratio (PE-TTM) of only 23.3 times, standing at the 3.86th percentile of the past year, meaning its valuation is lower than in more than 96.14% of the period over the past year, at a historical low level.

Penghua CSI Chinese Medicine ETFclosely tracks the CSI Traditional Chinese Medicine Index, which selects securities of listed companies engaged in the production and sales of traditional Chinese medicine as index constituents to reflect the overall performance of TCM-themed listed companies.

Data shows that as of March 31, 2026, the top ten weighted stocks of the CSI Traditional Chinese Medicine Index (930641) were

Yunnan Baiyao, Zhangzhou Pientzehuang, Dong-E E-Jiao, Tongrentang, China Resources Sanjiu, Jilin Aodong, Baiyunshan, Yiling Pharmaceutical, Zhongsheng Pharmaceutical, and Darentang,

with the top ten accounting for 55.08% of the total index weight.

(The stocks listed above are index constituents only and do not constitute specific investment recommendations.)

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.